Effect of atorvastatin on wound healing in rats. 2015

Vanessa Ferraz Suzuki-Banhesse, and Flávia Figueiredo Azevedo, and Eliana Pereira Araujo, and Maria Esméria Corezola do Amaral, and Andrea Moro Caricilli, and Mario Jose Abdalla Saad, and Maria Helena Melo Lima
Faculty of Nursing, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.

Skin-wound healing is a complex and dynamic biological process involving inflammation, proliferation, and remodeling. Recent studies have shown that statins are new therapeutical options because of their actions, such as anti-inflammatory and antioxidant activity, on vasodilation, endothelial dysfunction and neoangiogenesis, which are independent of their lipid-lowering action. Our aim was to investigate the effect of atorvastatin on tissue repair after acute injury in healthy animals. Rats were divided into four groups: placebo-treated (P), topical atorvastatin-treated (AT), oral atorvastatin-treated (AO), topical and oral atorvastatin-treated (ATO). Under anesthesia, rats were wounded with an 8-mm punch in the dorsal region. Lesions were photographed on Days 0, 1, 3, 7, 10, 12, and 14 post-injury and samples taken on Days 1, 3, 7, and 14 for protein-expression analysis of insulin receptor substrate (IRS)-1, phosphatidylinositol 3-kinase (PI3K), protein kinase B (Akt), glycogen synthase kinase (GSK)-3, endothelial nitric oxide synthase (eNOS), vascular endothelial growth factor (VEGF), extracellular signal-regulated kinase (ERK), interleukin (IL)-10, IL-1β, IL-6, and tumor necrosis factor (TNF)-α. Upon macroscopic examination, we observed significant reductions of lesion areas in groups AT, AO, and ATO compared to the P group. Additionally, AT and AO groups showed increased expression of IRS-1, PI3K, Akt, GSK-3, and IL-10 on Days 1 and 3 when compared with the P group. All atorvastatin-treated groups showed higher expression of IRS-1, PI3K, Akt, GSK-3, IL-10, eNOS, VEGF, and ERK on Day 7. On Days 1, 3, and 7, all atorvastatin-treated groups showed lower expression of IL-6 and TNF-α when compared with the P group. We conclude that atorvastatin accelerated tissue repair of acute lesions in rats and modulated expressions of proteins and cytokines associated with cell-growth pathways.

UI MeSH Term Description Entries
D008297 Male Males
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011972 Receptor, Insulin A cell surface receptor for INSULIN. It comprises a tetramer of two alpha and two beta subunits which are derived from cleavage of a single precursor protein. The receptor contains an intrinsic TYROSINE KINASE domain that is located within the beta subunit. Activation of the receptor by INSULIN results in numerous metabolic changes including increased uptake of GLUCOSE into the liver, muscle, and ADIPOSE TISSUE. Insulin Receptor,Insulin Receptor Protein-Tyrosine Kinase,Insulin Receptor alpha Subunit,Insulin Receptor beta Subunit,Insulin Receptor alpha Chain,Insulin Receptor beta Chain,Insulin-Dependent Tyrosine Protein Kinase,Receptors, Insulin,Insulin Receptor Protein Tyrosine Kinase,Insulin Receptors
D000069059 Atorvastatin A pyrrole and heptanoic acid derivative, HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITOR (statin), and ANTICHOLESTEREMIC AGENT that is used to reduce serum levels of LDL-CHOLESTEROL; APOLIPOPROTEIN B; and TRIGLYCERIDES. It is used to increase serum levels of HDL-CHOLESTEROL in the treatment of HYPERLIPIDEMIAS, and for the prevention of CARDIOVASCULAR DISEASES in patients with multiple risk factors. (3R,5R)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid,Atorvastatin Calcium,Atorvastatin Calcium Anhydrous,Atorvastatin Calcium Hydrate,Atorvastatin Calcium Trihydrate,Atorvastatin, Calcium Salt,CI 981,CI-981,Lipitor,Liptonorm,CI981
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D014945 Wound Healing Restoration of integrity to traumatized tissue. Healing, Wound,Healings, Wound,Wound Healings
D015151 Immunoblotting Immunologic method used for detecting or quantifying immunoreactive substances. The substance is identified by first immobilizing it by blotting onto a membrane and then tagging it with labeled antibodies. Dot Immunoblotting,Electroimmunoblotting,Immunoelectroblotting,Reverse Immunoblotting,Immunoblotting, Dot,Immunoblotting, Reverse,Dot Immunoblottings,Electroimmunoblottings,Immunoblottings,Immunoblottings, Dot,Immunoblottings, Reverse,Immunoelectroblottings,Reverse Immunoblottings

Related Publications

Vanessa Ferraz Suzuki-Banhesse, and Flávia Figueiredo Azevedo, and Eliana Pereira Araujo, and Maria Esméria Corezola do Amaral, and Andrea Moro Caricilli, and Mario Jose Abdalla Saad, and Maria Helena Melo Lima
January 1970, Radiation research,
Vanessa Ferraz Suzuki-Banhesse, and Flávia Figueiredo Azevedo, and Eliana Pereira Araujo, and Maria Esméria Corezola do Amaral, and Andrea Moro Caricilli, and Mario Jose Abdalla Saad, and Maria Helena Melo Lima
October 1986, Agents and actions,
Vanessa Ferraz Suzuki-Banhesse, and Flávia Figueiredo Azevedo, and Eliana Pereira Araujo, and Maria Esméria Corezola do Amaral, and Andrea Moro Caricilli, and Mario Jose Abdalla Saad, and Maria Helena Melo Lima
June 1971, American journal of surgery,
Vanessa Ferraz Suzuki-Banhesse, and Flávia Figueiredo Azevedo, and Eliana Pereira Araujo, and Maria Esméria Corezola do Amaral, and Andrea Moro Caricilli, and Mario Jose Abdalla Saad, and Maria Helena Melo Lima
May 1971, American journal of surgery,
Vanessa Ferraz Suzuki-Banhesse, and Flávia Figueiredo Azevedo, and Eliana Pereira Araujo, and Maria Esméria Corezola do Amaral, and Andrea Moro Caricilli, and Mario Jose Abdalla Saad, and Maria Helena Melo Lima
August 2009, Photomedicine and laser surgery,
Vanessa Ferraz Suzuki-Banhesse, and Flávia Figueiredo Azevedo, and Eliana Pereira Araujo, and Maria Esméria Corezola do Amaral, and Andrea Moro Caricilli, and Mario Jose Abdalla Saad, and Maria Helena Melo Lima
January 1989, Archives of dermatological research,
Vanessa Ferraz Suzuki-Banhesse, and Flávia Figueiredo Azevedo, and Eliana Pereira Araujo, and Maria Esméria Corezola do Amaral, and Andrea Moro Caricilli, and Mario Jose Abdalla Saad, and Maria Helena Melo Lima
March 1985, Surgery,
Vanessa Ferraz Suzuki-Banhesse, and Flávia Figueiredo Azevedo, and Eliana Pereira Araujo, and Maria Esméria Corezola do Amaral, and Andrea Moro Caricilli, and Mario Jose Abdalla Saad, and Maria Helena Melo Lima
March 2011, Clinical cancer research : an official journal of the American Association for Cancer Research,
Vanessa Ferraz Suzuki-Banhesse, and Flávia Figueiredo Azevedo, and Eliana Pereira Araujo, and Maria Esméria Corezola do Amaral, and Andrea Moro Caricilli, and Mario Jose Abdalla Saad, and Maria Helena Melo Lima
January 2005, Indian journal of physiology and pharmacology,
Vanessa Ferraz Suzuki-Banhesse, and Flávia Figueiredo Azevedo, and Eliana Pereira Araujo, and Maria Esméria Corezola do Amaral, and Andrea Moro Caricilli, and Mario Jose Abdalla Saad, and Maria Helena Melo Lima
April 1996, Arzneimittel-Forschung,
Copied contents to your clipboard!